The latest batch of product approvals in Japan includes the first to be granted anywhere globally for AbbVie Inc.'s anti-interleukin-23 antibody Skyrizi (risankizumab), as well as nods for Japan’s first gene-based therapy and a pioneering marketing clearance in Asia for a CAR-T drug, Novartis AG's Kymriah.
Skyrizi, being developed globally in a collaboration with Boehringer Ingelheim GmbH, was approved for plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?